CYTOMEDIX TO EXHIBIT AT THE 22ND ANNUAL SYMPOSIUM ON ADVANCED WOUND CARE AND WOUND HEALING SOCIETY (SAWC/WHS) MEETING
APRIL 26-29, 2009
AUTOLOGEL TO BE FEATURED IN TWO CLINICAL POSTER PRESENTATIONS
ROCKVILLE, MD., April 23,
2009 – Cytomedix, Inc. (NYSE
Alternext US:
GTF) today announced that it will be exhibiting at the
22nd Annual Symposium on Advanced Wound Care and Wound
Healing Society (SAWC/WHS) Meeting from April 26 through
April 29, 2009 at the Gaylord Texan Hotel and Convention
Center in Dallas, TX. Two clinical posters which demonstrate
positive outcomes of the AutoloGel™ System in challenging
chronic wound patients will be presented during the
symposium.
"We are very pleased to be participating in the SAWC/WHS
Meeting,” said Martin Rosendale, Chief Executive Officer of
Cytomedix. “In early 2009, we implemented a new sales
approach for the AutoloGel™ System, based on the scientific
rationale for the mechanism of action, which will be the
centerpiece of our exhibit. Additionally, we incorporated an
intensive clinical support program for our new and existing
customers. This approach has garnered acceptance by
clinicians, which we are eager to build on at the SAWC/WHS
Meeting. We are also particularly grateful that two
reputable medical professionals will be sharing the
encouraging results of their independent research on our
products in the form of poster presentations” continued
Rosendale. “We believe the increasing portfolio of positive
clinical evidence is indicative of growing awareness and
confidence in the AutoloGel™ technology by the medical
community,” he added.
The SAWC/WHS Meeting is the largest gathering of
multidisciplinary wound care clinicians in the United
States. The conference targets physicians, nurses, physical
therapists, researchers, podiatrists, dieticians, and
members of the medical industry involved in wound healing or
wound care issues. The conference provides attendees with
state-of-the-art reviews of clinical issues and research
information.
The two abstract presentations were supported by an
educational grant from Cytomedix, and will be available via
the respective links below beginning April 26, 2009:
Using Platelet Rich Plasma (PRP) Gel to Manage Complex Wounds in an LTAC
Theresa Hernandez, RN, CWS, Wound Care Coordinator; James C. Stern, M.D., FACS
LTAC Hospital, Hollywood, FL
Link: http://www.cytomedix.com/abstract-usingPRP_2009-0426.html
"Double impact”: Synergism in using Negative Pressure
Wound Therapy with alternated applications of Autologous
Platelet Derived Growth Factors in treating post acute
surgical wounds. Case series
L. Gurvich, ANP, MS, MPH, CWS
L.Weiss Memorial Hospital, Wound Healing Center Chicago, Illinois
Link: http://www.cytomedix.com/abstract-doubleimpact_2009-0426.html
ABOUT CYTOMEDIX
Cytomedix is a biotechnology company that develops, sells,
and licenses regenerative biological therapies, including
the AutoloGel™ System, a device for the production of
platelet rich plasma ("PRP'') gel derived from the patient's
own blood. The AutoloGel™ System is cleared by the Food and
Drug Administration ("FDA'') for use on a variety of exuding
wounds. Additional information regarding Cytomedix is
available at: http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to
historical facts are forward-looking statements that are
intended to fall within the safe harbor rule for such
statements under the Private Securities Litigation Reform
Act of 1995. The information contained in the
forward-looking statements is inherently uncertain, and
Cytomedix's actual results may differ materially due to a
number of factors, many of which are beyond Cytomedix's
ability to predict or control, including among others, the
outcome of development or regulatory review of CT-112,
commercial success or acceptance by the medical community,
competitive responses, viability and effectiveness of the
Company’s sales approach and overall marketing strategies,
and Cytomedix’s ability to execute on its strategy to market
the AutoloGel™ System as contemplated. These
forward-looking statements are subject to known and unknown
risks and uncertainties that could cause actual events to
differ from the forward-looking statements. More information
about some of these risks and uncertainties may be found in
the reports filed with the Securities and Exchange
Commission by Cytomedix, Inc. Cytomedix operates in a highly
competitive and rapidly changing business and regulatory
environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual
results. Except as is expressly required by the federal
securities laws, Cytomedix undertakes no obligation to
update or revise any forward-looking statements, whether as
a result of new information, changed circumstances or future
events or for any other reason. |
